Skyai, Inc. quarterly report, Q3 FY2022

Sharps Technology, Inc. — Form 10-Q Summary

Entity note: The request metadata names Skyai, Inc., but the supplied filing is for Sharps Technology, Inc. This summary reflects the filing provided. Reporting period: quarter and nine months ended September 30, 2022; financial statements are unaudited.

Business context

Sharps is a pre-revenue medical-device company developing and seeking to commercialize safety syringes. It acquired the Safegard manufacturing facility in Hungary on July 6, 2022. The company reported no revenue through the period and had an accumulated deficit of $14.46 million.

Financial performance and position

MetricThree months ended Sep. 30, 2022Nine months ended Sep. 30, 2022
Revenue$0$0
Research and development expense$457,627$1,520,870
General and administrative expense$1,339,448$4,401,158
Operating loss$1,797,075$5,922,028
Net loss$2,398,123$3,790,090
Net loss per share, basic and diluted$0.26$0.49
  • Quarterly net loss was $1.06 million greater than the prior-year quarter; nine-month net loss increased $723,506 year over year. Revenue remained zero, so revenue-based margins are not applicable.
  • Quarterly results included a $635,283 fair-value loss on warrant liabilities. For the nine-month period, other income included a $3.44 million fair-value gain on derivatives, partly offset by $1.33 million of net interest expense, including debt-discount accretion.
  • Cash was $6.39 million at September 30, versus $1.48 million at December 31, 2021. Working capital was $2.89 million, compared with a $1.16 million deficit at year-end 2021. Current liabilities included $3.10 million of warrant liabilities.
  • Nine-month cash flows: $4.39 million used in operations, $2.95 million used in investing, and $12.24 million provided by financing. Cash increased $4.91 million to $6.39 million.
  • Total assets were $13.53 million; total liabilities were $3.81 million and stockholders’ equity was $9.72 million. The $2.0 million secured bridge note was repaid using IPO proceeds; no notes payable remained at period-end. The filing does not provide a specific cash-runway estimate.

Material changes and transactions

  • The April 2022 IPO generated approximately $14.2 million in net proceeds before certain warrant-related accounting effects; proceeds funded repayment of the bridge note and operations and investment. Cash increased substantially, and common shares outstanding rose to 9,207,415 at September 30.
  • Safegard’s acquisition cost was $2.94 million. The acquired assets included land, building and affixed assets, machinery, inventory, and intangibles. Fixed assets, net, increased to $6.64 million from $3.76 million at year-end.
  • Operating expenses increased year over year: quarterly R&D rose 29% and G&A rose 36%; nine-month R&D rose 27% and G&A rose 136%. Management attributed the increases to staffing and Safegard-related activity, public-company costs, professional fees, insurance, marketing, and equipment depreciation.
  • Warrants issued with the IPO and to bridge-note investors are classified as liabilities and remeasured at fair value, creating potentially significant non-cash earnings volatility. Warrant liability was $3.10 million at quarter-end.

Outlook, risks, and contingencies

  • Management expects R&D expense to increase as it develops the Sharps Provensa product line. The company said commercial quantities of inventory are needed to secure orders; it gave no financial forecast or quantified guidance.
  • A September 29, 2022 agreement with Nephron Pharmaceuticals Corporation runs initially through September 2026. The parties described plans for further manufacturing-supply, pharmaceutical-services, and possible expansion agreements, with product supply projected by management to begin in mid-2023. These plans are prospective and depend on further development and agreements.
  • The company reported no material litigation or other material loss contingencies. A 2% royalty on certain related product net sales remains in effect because a proposed $500,000 buyout payment was not made.
  • Open equipment and mold orders totaled $239,664, with $111,013 recorded as deposits. After quarter-end, the company entered a one-year marketing and investor-relations agreement providing for a $90,000 initial fee, $12,500 monthly fees, $300,000 for digital marketing, and 200,000 restricted shares; the filing says the initial and first monthly fees and shares were issued after September 30.
  • Management concluded disclosure controls were effective and reported no material change in internal control. The filing identifies no material change to the IPO prospectus risk factors. The company remains dependent on successful development, commercialization, financing, and execution of planned partnerships.

Important facts for investors to verify

  • Confirm the issuer identity: the request says Skyai, Inc., while this filing identifies Sharps Technology, Inc. (STSS).
  • Track progress toward product commercialization, required regulatory and quality standards, customer orders, and the stated Nephron supply timeline and follow-on agreements.
  • Assess cash burn against the $6.39 million period-end cash balance, including the post-period marketing commitment and planned expansion needs.
  • Review warrant terms, fair-value changes, potential dilution, and the reported 10.55 million options and warrants excluded from diluted loss per share as anti-dilutive.
  • Reconcile share counts and subsequent issuances: 9,207,415 common shares were outstanding at September 30, and 9,407,415 were reported outstanding on November 14, 2022.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.